Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 10INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Multiple Myeloma 14Recurrence 6Neoplasms 6Leukemia, Myeloid, Acute 6Prostatic Neoplasms 5Lymphoma, T-Cell, Cutaneous 4Neoplasms, Plasma Cell 3Lymphoma 3Leukemia 3Sezary Syndrome 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Leukemia, Myelomonocytic, Chronic 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Solid Tumors 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Thalassemia 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1

Interventions

Brentuximab Vedotin 27pembrolizumab 13Nivolumab 11Dacarbazine 8Vinblastine 7Doxorubicin 7Gemcitabine 6Bendamustine Hydrochloride 6plerixafor 5fludarabine 4Rituximab 4Granulocyte Colony-Stimulating Factor 4Cyclophosphamide 4Azacitidine 4abexinostat 3Melphalan 3Filgrastim 3Etoposide 3Busulfan 3Bleomycin 3umbralisib 2relatlimab 2pegfilgrastim 2mocetinostat 2itacitinib 2givinostat hydrochloride 2givinostat 2fludarabine phosphate 2durvalumab 2cc-486 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Hodgkin Disease × Panobinostat × Clear all
NCT00742027 2021-07-28

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Novartis

Phase 2 Completed
129 enrolled 16 charts
Lymphoid

Hodgkin Disease

NCT01034163 2016-07-07

PATH

Novartis

Phase 3 Completed
41 enrolled 7 charts
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡